Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors

Thrombosis Research

Volumn 106, Issue 1, 2002, Pages 25-29

  Weber, Artur Aron ^a   Meila, Dan ^a   Jacobs, Collin ^a   Weber, Stephanie ^b   Kelm, Malte ^a   Strauer, Bodo E ^a   Zotz, Rainer B ^a   Scharf, Rüdiger E ^a   Schrör, Karsten ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Evotec Technologies   (Germany)

Author keywords

Abciximab; Eptifibatide; Glycoprotein; Platelet; Polymorphism; Tirofiban

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; PADGEM PROTEIN; THROMBOCYTE ANTIGEN; TIROFIBAN; 1A ALLOANTIGEN, HUMAN; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; HUMAN PLATELET ANTIGEN 1B; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE; TYROSINE;

ADULT; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; DRUG EFFECT; FEMALE; FLUORESCENCE SPECTROSCOPY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ANTAGONISM; GENETIC POLYMORPHISM; GENETICS; INCIDENCE; MIDDLE AGED;

ADENOSINE DIPHOSPHATE; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, HUMAN PLATELET; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; FEMALE; GENOTYPE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INCIDENCE; MALE; MIDDLE AGED; P-SELECTIN; PEPTIDES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMORPHISM, GENETIC; TYROSINE;

EID: 0036544668     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00083-X     Document Type: Article

References (19)

1. 3) inhibitors
2. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy
3. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation
4. Paradoxical platelet activation was not observed on dissociation of abciximab from GPIIb-IIIa complexes
5. Platelet activation as a potential mechanism of GPIIb/IIIa inhibitor-induced thrombocytopenia
6. A polymorphisms display different sensitivities to agonists
7. A2 polymorphism
8. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel
9. Genotyping of human platelet antigen-1 by gene amplification and labelling in one system and automated fluorescence correlation spectroscopy (FCS)
10. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics
11. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with coronary artery disease
12. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial
13. Differences between activation thresholds for platelet P-selectin and glycoprotein IIb-IIIa expression and their clinical implications
14. Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease
15. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: The Framingham Offspring Study
16. Platelet hyperreactivity after coronary artery bypass grafting: The possible relevance to glycoprotein polymorphisms. A preliminary report
17. Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets
18. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa
19. Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab